MA52796A - Compositions et procédés de détection d'une lésion cérébrale traumatique - Google Patents
Compositions et procédés de détection d'une lésion cérébrale traumatiqueInfo
- Publication number
- MA52796A MA52796A MA052796A MA52796A MA52796A MA 52796 A MA52796 A MA 52796A MA 052796 A MA052796 A MA 052796A MA 52796 A MA52796 A MA 52796A MA 52796 A MA52796 A MA 52796A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- detection
- methods
- brain injury
- traumatic brain
- Prior art date
Links
- 208000030886 Traumatic Brain injury Diseases 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009529 traumatic brain injury Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Eye Examination Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678900P | 2018-05-31 | 2018-05-31 | |
| US201862733025P | 2018-09-18 | 2018-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52796A true MA52796A (fr) | 2021-04-14 |
Family
ID=68697319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052796A MA52796A (fr) | 2018-05-31 | 2019-05-31 | Compositions et procédés de détection d'une lésion cérébrale traumatique |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12478693B2 (fr) |
| EP (1) | EP3803416A4 (fr) |
| JP (3) | JP7381500B2 (fr) |
| CN (2) | CN112424606B9 (fr) |
| AU (1) | AU2019279001B2 (fr) |
| CA (1) | CA3100700A1 (fr) |
| MA (1) | MA52796A (fr) |
| WO (1) | WO2019232422A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019372432B2 (en) * | 2018-11-02 | 2025-05-29 | Amydis, Inc. | Phosphate compounds for detecting neurological disorders |
| AU2020348382A1 (en) * | 2019-09-18 | 2022-04-28 | Amydis, Inc. | Methods of detecting neurological disorders via binding to phosphorylated tau protein |
| JP2024525693A (ja) * | 2021-07-15 | 2024-07-12 | アミディス, インコーポレイテッド | 神経変性障害の診断のためにアミロイドおよびアミロイド様タンパク質を検出するためのフルオロフォアとしてのn-ヘテロシクリル置換2-シアノ-3-(ナフタレン-2-イル)アクリルアミド誘導体 |
| WO2024155678A1 (fr) * | 2023-01-18 | 2024-07-25 | Amydis, Inc. | Agents de ciblage d'amyloïde |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043013A (en) | 1987-12-30 | 1991-08-27 | Milliken Research Corporation | Washable ink compositions |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| US6541454B1 (en) | 1995-04-04 | 2003-04-01 | Yissum Research Development Company Of The Hebrew University Jerusalem | Phosphonates, biphosphonates and pharmaceutical compositions containing them |
| US6048662A (en) | 1998-12-15 | 2000-04-11 | Bruhnke; John D. | Antireflective coatings comprising poly(oxyalkylene) colorants |
| DE10047237A1 (de) | 2000-09-23 | 2002-04-11 | Physoptics Opto Electronic Gmb | System zur Aufnahme des Netzhautreflexbildes |
| JPWO2003020690A1 (ja) | 2001-08-29 | 2004-12-16 | 協和醗酵工業株式会社 | アリールスルファマート誘導体 |
| JP2007504283A (ja) | 2003-05-20 | 2007-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | β−アミロイド斑に作用物質を結合させる方法 |
| CN101103018A (zh) * | 2004-11-16 | 2008-01-09 | 神经化学(国际)有限公司 | 治疗cns和淀粉样蛋白-相关疾病的化合物 |
| ATE525664T1 (de) | 2004-11-22 | 2011-10-15 | Abbott Medical Optics Inc | Copolymerisierbare methin- und anthrachinon- verbindungen und artikel damit |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| JP2008013446A (ja) | 2006-07-03 | 2008-01-24 | Neugen Pharma:Kk | 酸化ストレスによる細胞変性を分子背景とする難治性疾患の治療または予防剤 |
| EP2046322A4 (fr) | 2006-08-02 | 2010-10-06 | Univ Temple | Aryl vinyl sulfures, sulfones, sulfoxides et sulfonamides, dérivés de ceux-ci et utilisations thérapeutiques de ceux-ci |
| WO2009086303A2 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
| EP3231804B1 (fr) | 2008-03-21 | 2021-03-03 | The General Hospital Corporation | Composés et compositions pour la détection et le traitement de la maladie d'alzheimer et des troubles apparentés |
| JP5771525B2 (ja) | 2008-09-18 | 2015-09-02 | セダーズ−シナイ メディカル センター | アルツハイマー病を検出するための光学的方法 |
| US20120282169A1 (en) | 2009-11-06 | 2012-11-08 | Adlyfe, Inc. | Detection and treatment of traumatic brain injury |
| SI2509940T1 (sl) | 2009-12-10 | 2015-09-30 | The Regents Of The University Of California | Sredstva za vezavo amiloida |
| CN102115429B (zh) | 2010-01-06 | 2013-02-27 | 中国科学院上海药物研究所 | (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途 |
| KR101194337B1 (ko) | 2010-07-14 | 2012-10-24 | 웅진코웨이주식회사 | 레티노이드 유도체 및 그를 포함하는 화장료 조성물 |
| CA2807683C (fr) | 2010-08-16 | 2020-02-18 | Cognoptix, Inc. | Systeme et procede pour la detection de proteines amyloides |
| CA2814198A1 (fr) | 2010-10-25 | 2012-05-10 | Steven Verdooner | Appareil et procede de detection d'amyloide dans une retine dans un diagnostic, un avancement et un pronostic de la maladie d'alzheimer, d'une lesion cerebrale traumatique, d'une degenerescence maculaire et d'une pluralite de maladies neurodegeneratives, et de maladies oculaires |
| RU2627694C2 (ru) | 2010-10-29 | 2017-08-10 | Клино Лтд. | Производные хинолина, визуализирующий белок тау |
| US9588129B2 (en) | 2013-03-15 | 2017-03-07 | Amira Medical Technologies Inc. | Methods for analyzing blood to detect diseases associated with abnormal protein aggregation |
| EP3068388A4 (fr) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Composés neuroprotecteurs et leur utilisation |
| EP3068283A1 (fr) | 2013-11-12 | 2016-09-21 | Cognoptix, Inc. | Procédé de mesure de fluorescence dans le tissu oculaire |
| AU2015231239B2 (en) | 2014-03-19 | 2018-11-29 | Amydis, Inc. | Amyloid targeting agents and methods of using the same |
| US9605315B2 (en) * | 2014-03-26 | 2017-03-28 | The University Of Montana | Detection of traumatic brain injury |
| WO2015188142A1 (fr) | 2014-06-05 | 2015-12-10 | Cedars-Sinai Medical Center | Diagnostic et surveillance d'une lésion cérébrale traumatique par imagerie des anomalies rétiniennes |
| WO2016040891A2 (fr) | 2014-09-12 | 2016-03-17 | Amydis Diagnostics | Compositions in vitro comprenant un échantillon humain et un agent ciblant les substances amyloïdes |
| WO2016055148A2 (fr) | 2014-10-06 | 2016-04-14 | Université De Genève | Marqueurs et leur utilisation en lien avec une lésion cérébrale |
| WO2017004560A1 (fr) * | 2015-07-02 | 2017-01-05 | The Regents Of The University Of California | Procédés et compositions pour des agrégats amyloïdes |
| GB201603967D0 (en) | 2016-03-08 | 2016-04-20 | Univ Birmingham | Biomarkers of traumatic brain injury |
| JP7029718B2 (ja) | 2017-07-31 | 2022-03-04 | 国立研究開発法人量子科学技術研究開発機構 | リン酸化タウタンパク質の測定方法 |
| AU2019372432B2 (en) * | 2018-11-02 | 2025-05-29 | Amydis, Inc. | Phosphate compounds for detecting neurological disorders |
| AU2020348382A1 (en) | 2019-09-18 | 2022-04-28 | Amydis, Inc. | Methods of detecting neurological disorders via binding to phosphorylated tau protein |
| IL305647A (en) | 2021-03-12 | 2023-11-01 | Amydis Inc | Methods for the detection of systemic amyloidosis by binding to misfolded protein or aggregates |
| JP2024525693A (ja) | 2021-07-15 | 2024-07-12 | アミディス, インコーポレイテッド | 神経変性障害の診断のためにアミロイドおよびアミロイド様タンパク質を検出するためのフルオロフォアとしてのn-ヘテロシクリル置換2-シアノ-3-(ナフタレン-2-イル)アクリルアミド誘導体 |
| WO2024155678A1 (fr) | 2023-01-18 | 2024-07-25 | Amydis, Inc. | Agents de ciblage d'amyloïde |
-
2019
- 2019-05-31 MA MA052796A patent/MA52796A/fr unknown
- 2019-05-31 WO PCT/US2019/034977 patent/WO2019232422A1/fr not_active Ceased
- 2019-05-31 JP JP2020567093A patent/JP7381500B2/ja active Active
- 2019-05-31 CN CN201980044404.1A patent/CN112424606B9/zh active Active
- 2019-05-31 US US16/973,028 patent/US12478693B2/en active Active
- 2019-05-31 CN CN202411990187.4A patent/CN119985995A/zh active Pending
- 2019-05-31 AU AU2019279001A patent/AU2019279001B2/en active Active
- 2019-05-31 EP EP19810892.0A patent/EP3803416A4/fr active Pending
- 2019-05-31 CA CA3100700A patent/CA3100700A1/fr active Pending
-
2023
- 2023-11-02 JP JP2023188467A patent/JP7583895B2/ja active Active
-
2024
- 2024-11-01 JP JP2024192794A patent/JP2025016675A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210369873A1 (en) | 2021-12-02 |
| CN112424606B9 (zh) | 2025-03-07 |
| JP2025016675A (ja) | 2025-02-04 |
| EP3803416A4 (fr) | 2022-05-18 |
| JP2021525875A (ja) | 2021-09-27 |
| JP7381500B2 (ja) | 2023-11-15 |
| AU2019279001B2 (en) | 2025-11-27 |
| JP2024028695A (ja) | 2024-03-05 |
| CA3100700A1 (fr) | 2019-12-05 |
| CN112424606A (zh) | 2021-02-26 |
| US12478693B2 (en) | 2025-11-25 |
| WO2019232422A1 (fr) | 2019-12-05 |
| CN112424606B (zh) | 2025-01-14 |
| EP3803416A1 (fr) | 2021-04-14 |
| JP7583895B2 (ja) | 2024-11-14 |
| CN119985995A (zh) | 2025-05-13 |
| AU2019279001A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3704239A4 (fr) | Compositions de casz et procédés d'utilisation | |
| EP3630072A4 (fr) | Procédés et compositions pour le traitement d'une somnolence excessive | |
| MA43822A (fr) | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides | |
| MA46905A (fr) | Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides | |
| EP3377042A4 (fr) | Substances et procédés de traitement de myopathies à base de titine et d'autres titinopathies | |
| MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3474879A4 (fr) | Compositions et procédés de traitement d'un mélanome | |
| EP3510171A4 (fr) | Compositions et procédés pour la détection de mutations d'acides nucléiques | |
| MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
| MA44990A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1 | |
| MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
| EP3350315A4 (fr) | Procédés pour l'édition autocatalytique de génome et la neutralisation de l'édition autocatalytique de génome et leurs compositions | |
| EP3320093A4 (fr) | Compositions et procédés d'identification, d'évaluation, de prévention et de traitement du cancer à l'aide d'isoformes de slncr | |
| EP3289064A4 (fr) | Compositions et procédés pour la détection d'allergènes | |
| EP3512351A4 (fr) | Compositions et procédés d'amélioration de goût d'édulcorants non nutritifs | |
| EP3836926A4 (fr) | Procédés d'administration de certains inhibiteurs de vmat2 | |
| EP3448421A4 (fr) | Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales | |
| MA52796A (fr) | Compositions et procédés de détection d'une lésion cérébrale traumatique | |
| MA53445A (fr) | Procédés et compositions pour la modification de plantes | |
| EP3390642A4 (fr) | Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13 | |
| EP3833340A4 (fr) | Compositions et procédés de traitement de la presbytie | |
| EP3803403A4 (fr) | Compositions et procédés d'imagerie | |
| EP3810109A4 (fr) | Compositions et procédés d'inhibition de cd73 | |
| EP3426391A4 (fr) | Compositions et procédés d'acylation de lactames | |
| EP3873525A4 (fr) | Compositions et procédés de traitement d'une lésion cérébrale |